Abstract |
The Lewis X ( Le(X)) antigen is a prognostic marker in certain solid tumors and has been proposed as a therapeutic target. Immunohistochemical analyses were performed to retrospectively examine the prognostic impact of Le(X) expression in 158 patients with triple-negative breast cancer (TNBC). Twenty-three (14.5%) patients were Le(X)-positive. Multivariate analysis showed that Le(X) positivity was an independent poor prognostic factor for recurrence-free survival (RFS) and overall survival (OS) (P = .037 and P = .024, respectively). Le(X) expression was a prognostic factor for survival in stage I/II and stage III TNBCs. Subgroup analysis according to age showed that Le(X) positivity was only associated with poor RFS and OS in younger patients with TNBC (age < 50 years) (P < .001 and P < .001, respectively). Our results suggest that Le(X) expression is an independent prognostic factor for RFS and OS in younger patients with TNBC.
|
Authors | Young Wha Koh, Hee Jin Lee, Jin-Hee Ahn, Jong Won Lee, Gyungyub Gong |
Journal | American journal of clinical pathology
(Am J Clin Pathol)
Vol. 139
Issue 6
Pg. 746-53
(Jun 2013)
ISSN: 1943-7722 [Electronic] England |
PMID | 23690116
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Lewis Blood Group Antigens
- Lewis X Antigen
|
Topics |
- Biomarkers, Tumor
(biosynthesis)
- Breast Neoplasms
(immunology, mortality, pathology)
- Disease-Free Survival
- Female
- Humans
- Lewis Blood Group Antigens
(immunology)
- Lewis X Antigen
(biosynthesis)
- Middle Aged
- Prognosis
- Retrospective Studies
|